Quantum BioPharma Ltd. (QNTM)
NASDAQ: QNTM · Real-Time Price · USD
4.880
-0.130 (-2.59%)
At close: May 8, 2026, 4:00 PM EDT
4.980
+0.100 (2.05%)
After-hours: May 8, 2026, 7:18 PM EDT
Quantum BioPharma Employees
Quantum BioPharma had 17 employees as of December 31, 2022. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
n/a
Profits / Employee
-$1,832,874
Market Cap
28.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2022 | 17 | 7 | 70.00% | 17 | 0 |
| Dec 31, 2021 | 10 | 1 | 11.11% | 10 | 0 |
| Dec 31, 2020 | 9 | -9 | -50.00% | 9 | 0 |
| Dec 31, 2019 | 18 | -1 | -5.26% | 17 | 1 |
| Sep 30, 2019 | 23 | 4 | 21.05% | 23 | 0 |
| Jun 30, 2019 | 19 | - | - | 19 | 0 |
| Dec 31, 2018 | 19 | - | - | 19 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Werewolf Therapeutics | 39 |
| Senti Biosciences Holdings | 39 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| Tevogen Bio Holdings | 18 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
QNTM News
- 2 days ago - Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 - GlobeNewsWire
- 11 days ago - Quantum BioPharma Provides Corporate Update - GlobeNewsWire
- 17 days ago - Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma submits Lucid-21-302 new drug application to the FDA - TheFly
- 5 weeks ago - Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - GlobeNewsWire
- 5 weeks ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly
- 5 weeks ago - Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial - TheFly
- 5 weeks ago - Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis - GlobeNewsWire